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Introduction: Colorectal cancer (CRC) is the third leading cause of cancer-related death in
the U.S. Many patients with CRC develop hepatic metastases as the sole site of metas-
tases. Historical treatment options were limited to resection or conventional radiation
therapy. Stereotactic body radiation therapy (SBRT) has emerged as a rational treatment
approach.This study reviews our experience with SBRT for patients with liver metastases
from CRC.Materials andMethods: Fourteen histologically conﬁrmed hepatic CRCmetas-
tases in 11 consecutive patients were identiﬁed between November, 2004 and June, 2009
at Georgetown University. All patients underwent CT-based treatment planning; a few also
had MRI or PET/CT. All patients had ﬁducial markers placed under CT guidance and were
treated using the CyberKnife system. Treatment response and toxicities were examined;
survival and local control were evaluated. Results: Most patients were treated to a single
hepatic lesion (n= 8), with a few treated to two lesions (n= 3). Median treatment volume
was 99.7 cm3, and lesionswere treated to amedian BED10 of 49.7Gy (range: 28–100.8Gy).
Median follow-up was 21months; median survival was 16.1months, with 2 year actuarial
survival of 25.7%. One year local control was 72%. Among patients with post-treatment
imaging, eight had stable disease (80%) and two had progressive disease (20%) at ﬁrst
follow-up. The most common grade 1–2 acute toxicities included nausea and alterations
in liver function tests; there was one grade 3 toxicity (elevated bilirubin), and no grade
4–5 toxicities. Discussion: SBRT is safe and feasible for the treatment of limited hepatic
metastases from CRC. Our results compare favorably with outcomes from previous stud-
ies of SBRT. Further studies are needed to better deﬁne patient eligibility, study the role of
combined modality treatment, optimize treatment parameters, and characterize quality of
life after treatment.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer, with 141,210 estimated new diagnoses in 2011 in the U.S.,
and it is the third leading cause of death, with 49,380 estimated
deaths in 2011 (Siegel et al., 2011). Metastatic disease is common,
and has been shown to be present in 25% of patients at initial
diagnosis, and up to 50% of patients over the course of their dis-
ease (Taylor, 1996). Autopsy series have demonstrated that some
patients with metastatic CRC die with the liver being the ﬁrst and
solitary site of metastatic disease (Weiss et al., 1986).
Limited metastatic disease to the liver is primarily managed
by surgical resection (Scheele et al., 1990). For patients under-
going resection, historical series have shown 5 year survivals of
25–39%, andmoremodern studies of highly selected patients have
demonstrated 5 year survival rates up to 67% (Fong et al., 1995;
Simmonds et al., 2006). However, the best surgical outcomes are
obtained in patients with low CEA levels, few metastases, small
lesions, limited resection volume, and clear post-operative mar-
gins (Cady et al., 1998; Fong et al., 1999). Traditionally, surgical
resection has only been offered to 10–20% of presenting patients,
although the criteria for operability have expanded. Using mul-
timodality approaches and re-centering resectability on hepatic
functional reserve and the likelihood of negative margins (Adam,
2003; Pawlik et al., 2008). However, many patients with metastatic
disease will either have lesions that are not amenable to surgery
due to compromised hepatic reserve or the small likelihood of neg-
ative margins; or they may be unﬁt for surgeries due to medical
comorbidities, functional status, or progression of disease out-
side of the liver. Twenty percent of patients may refuse resection
(Alberts et al., 2005; Garden et al., 2006).
Non-conformal RT has had a limited role in treatment of
hepatic metastases since radiation-induced liver disease (RILD)
has been linked to mean liver dose (Lawrence et al., 1992; Cheng
et al., 2002). Modern RT techniques can minimize dose to normal
liver with 3D-conformal radiation therapy or intensity-modulated
radiation therapy (IMRT; Krishnan et al., 2006). However, even
these technical advances can still deposit low-dose radiation in
a large volume of liver, continuing to limit dose-escalation for
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effective tumor control. The majority of liver tumors move with
the respiratory cycle. This movement requires the addition of
treatment margin, which increases the dose delivered to nor-
mal tissue. While it is important to limit dose to normal liver,
further studies have demonstrated the important impact of dose-
escalation of RT on control of hepatic metastases from CRC
(Mohiuddin et al., 1996; Dawson et al., 2000).
Stereotactic body radiation therapy (SBRT) has been success-
fully employed for the treatment of tumors in various disease sites.
Historically, single- or multi-fraction SBRT has been employed
for the treatment of brain metastases (Kondziolka, 2005; Aoyama
et al., 2006), andmore recently it has been successfully used for the
treatment of early stage lung cancer (Grills et al., 2010; Timmer-
man et al., 2010). For patients with limited liver metastasis from
CRC who are not surgical candidates or refuse surgery, SBRT is a
rational treatment approach, allowing for dose-escalation to the
tumor volumewhileminimizingdosedelivered to adjacent normal
tissue. SBRT with respiratory tracking for liver tumors has been
shown to be feasible (Wurm et al., 2006), while permitting effec-
tive dose-escalation and maintaining quality of life (Schefter et al.,
2005; Mendez Romero et al., 2008; Goodman et al., 2010). In this
study, we aim to review our experience with treating patients with
liver metastases from CRC and demonstrate the safety, feasibility,
and early outcomes of hypofractionated, image-guided SBRTwith
implanted ﬁducial markers.
MATERIALS AND METHODS
PATIENT SELECTION
This retrospective reviewwas approved by the Institutional Review
Board (IRB) of Georgetown University. Fourteen lesions in 11
consecutive patients treated with SBRT for liver metastases from
histologically conﬁrmed CRC between November, 2004 and June,
2009 were identiﬁed from treatment records at Georgetown Uni-
versity Hospital’s Department of Radiation Oncology. All patients
were not considered candidates for surgical resection. Lesions
were considered for treatment in any location within the liver,
including right, left, and caudate lobes, as well as proximal to the
porta hepatis. Patients were included irrespective of prior treat-
ment, including prior treatment with chemotherapy, surgery, or
radiation therapy. Patients generally were expected to have a life
expectancy greater than 6months and adequate hepatic function.
SBRT PLANNING AND TREATMENT
All patients had three to ﬁve gold ﬁducials placed under CT
guidance (Best Medical, Springﬁeld, VA, USA). An example of
CT-guided placement of ﬁducial markers is shown in Figure 1.
A treatment planning CT scan with IV contrast and slice thick-
ness of 1–3mm was obtained greater than 5 days after ﬁducial
placement. Patients were simulated in the supine position. A gross
tumor volume (GTV)was delineated on the CT scan. To aid in tar-
get delineation, two patients also had MRIs and one patient had a
PET scan fused with their treatment planning CT scans. Typically,
amargin of at least 3–5mmwas added to theGTV to form the clin-
ical target volume (CTV). This expansion is similar to the 5mm
expansion used in an ongoing Accuray trial of CyberKnife liver
SBRT (Clinicaltrials.gov, 2011a), and the 5mm expansion used in
the RTOG 0438 Phase I trial for liver SBRT (Radiation Therapy
FIGURE 1 | (A) Fiducial placement, (B) fiducial placement.
Oncology Group, 2011). No additional margin was added to form
the planning target volume (PTV), due to the accuracy of ﬁducial
tracking. Adjacent critical structures were delineated. An example
of pre-treatment CT scan is shown in Figure 2.
All treatments were performed using the CyberKnife system
and were planned using Multiplan treatment planning software.
Radiation plans and dose prescriptions were developed using an
inverse-planning methodology. Treatments were delivered using
6MV photons from the CyberKnife system and were prescribed
to the isodose line that provided adequate coverage of the PTV
(>95%). Synchrony Respiratory Tracking Systemwas used to con-
tinuously track ﬁducial position and adjust for respiratorymotion
during treatment. Patientswere treated to amediandose of 28.5Gy
(range: 16–42Gy), in a median of three fractions (range: 2–5). A
biologic equivalent dose (BED) was calculated for each fraction-
ation scheme by the formula: BED10 = (prescription dose)× [1+
(dose per fraction/α/β)]; were α/β is assumed to be 10. A sample
treatment plan is shown in Figure 3.
DATA ANALYSIS
Treatment response was evaluated by serial CT, PET, and/or MRI
scans. Estimates of initial treatment response were determined
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FIGURE 2 | Pre-treatment CT scan.
FIGURE 3 |Treatment plan. Red= 88%; green= 73%; blue= 50%;
yellow= 20% isodose line.
using the response evaluation criteria in solid tumors (RECIST;
Eisenhauer et al., 2009). Local control was deﬁned as no evidence
of tumor growth of the treated lesion. Actuarial survival and local
control rates were evaluated by the Kaplan–Meier method. Uni-
variate analysis was performed with the log rank test. Toxicities
were evaluated according to the common terminology criteria for
adverse events (CTCAE), Version 4.0 (National Cancer Institute,
2010). Toxicities occurring less than or equal to 3months follow-
ing SBRT were considered acute, while toxicities occurring after
3months were considered late.
RESULTS
PATIENT CHARACTERISTICS
Patient and lesion characteristics are noted in Table 1. Most
patients were male (10) and had a median age at the time of SBRT
of 69 years old. Three patientswere treated to two liver lesions each,
and eight patients were each treated to a single hepatic lesion.Most
Table 1 | Patient characteristics.
Characteristic n(%)
Total patients (n) 11
Total lesions 14
Sex (n, %; per patient)
M 10 (91)
F 1 (9)
Age (years; per patient)
Median 69
Range 36–91
Number of liver lesions (per patient)
One 5 (45)
Two 1 (9)
Three or more 5 (45)
Location of lesion (per lesion)
Right lobe 8 (57)
Left lobe 3 (21)
Porta hepatis 2 (14)
Caudate 2 (14)
Prior therapy to treated lesion
Surgery 2 (14)
Chemotherapy 7 (50)
Radiation therapy 3 (21)
lesions were in the right lobe of the liver (eight), with few in the
left lobe (three), porta hepatis (two), or caudate (two).
TREATMENT PARAMETERS
For 12 of the lesions (86%), CT was the only treatment plan-
ning study performed. Lesions had a wide range of volumes, with
median volume of 99.7 cm3 (range: 21–225 cm3; Table 2). Patients
were treated to a median BED10 of 49.7Gy (range: 28–100.8Gy).
Patients were treated over a median course of 3 days (range: 1–
13 days). Themedianprescription isodose linewas 75%(65–90%).
Comprehensive treatment variables are listed in Table 2.
CLINICAL OUTCOMES
With a median follow-up of 21months, the median survival was
16.1months and the 2 year actuarial overall survival was 25.7%.Of
the lesions with evaluable post-treatment radiographic imaging,
eight had stable disease (80%), and two had progressive dis-
ease (20%) at ﬁrst imaging follow-up. An example of treatment
response as determined by CT scan is demonstrated in Figure 4.
Noneof these patients had a complete or partial response.One year
Kaplan–Meier estimate of local control was 72%, and only three
lesions demonstrated radiographic evidence of local failure at last
follow-up. On univariate analysis, the only factor associated with
local failure was initial RECIST response to SBRT (p = 0.0047).
None of the remaining factors, including BED10, conformality
index, prescription isodose line, and location within the liver were
statistically signiﬁcantly associated with local failure.
TOXICITY
Toxicities were evaluated according to the CTCAE, Version 4.0.
The most common acute toxicities included nausea (three) and
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Table 2 | Dosimetric parameters.
Characteristic n(%)
Planning studies
CT only 12 (86)
PET 1 (7)
MRI 2 (14)
Tumor volume, cm3
Mean 120.9
Median 99.7
Range 21–225
Prescribed dose, Gy
Mean 28.8
Median 28.5
Range 16–42
Number of fractions
Median 3
Range 2–5
Median dose per fraction 8.3Gy
Treatment duration (days)
Median 3
Range 1–13
BED10, Gy
Mean 55.1
Median 49.7
Range 28–100.8
Prescription isodose line, %
Mean 74.6
Median 75
Range 65–90
Conformality index
Mean 1.7
Median 1.7
Range 1.2–2.54
alterations in liver function tests (two). There was only one grade
3 toxicity (elevated bilirubin), and no grade 4 or 5 toxicities.
DISCUSSION
The results from our retrospective case series demonstrate the
safety and feasibility of hypofractionated SBRT for the treatment
of livermetastases fromCRC.During treatment, tumorswere con-
tinuously tracked by implanted ﬁducialmarkers, allowing a reduc-
tion in tumor margins. With a median follow-up of 21months,
the 1 year local control rate was 72% and 2 year overall survival
rate was 26%. The treatment was well tolerated, with only one
patient developing a grade 3 elevation of bilirubin. Importantly,
treatment was generally delivered in less than 2weeks, allowing for
rapid resumption of systemic therapy.
PREVIOUS EXPERIENCE WITH LIVER SBRT
Several previous series have been published evaluating the use of
SBRT for the treatment of liver metastases from multiple primary
sites (Katz et al., 2007; Lee et al., 2009; Rule et al., 2011). In a phase
I dose-escalation study, local control was 57% at 20months, with
median OS of 14.5months, and 1 year progression-fee survival
FIGURE 4 | (A) One month post-treatment CT scan, (B) 10month
post-treatment CT scan.
24% (Katz et al., 2007). A review of several case series demon-
strated excellent local control rates (78–100%), limited grade 1–2
acute toxicity (0–29%), and minimal grade 3–4 toxicity (0–5%;
Katz et al., 2007). A recent dose-escalation study that treated a
large median volume of normal liver (39%) demonstrated safety
and efﬁcacy of SBRT doses up to 60Gy delivered in up to six frac-
tions over 2weeks, noting that themaximum safely tolerated doses
may be even higher (Lee et al., 2009).
Speciﬁcally for CRC metastases to the liver, one group treated
patients in the same regimen as a current prospective trial, with
15Gy in three fractions; 19% of those patients were without dis-
ease progression after 2 years, and OS at 2 years was 38% (Hoyer
et al., 2006). In contrast to our study, signiﬁcant toxicity was
observed, including hepatic failure leading to death, colonic per-
foration, and duodenal ulcerations (Hoyer et al., 2006). A pooled
analysis demonstrated that total dose, dose per fraction, and BED
correlated with local control; inactive extrahepatic disease was
associated with overall survival; and local control was strongly
correlated with OS, emphasizing the signiﬁcance of controlling
intra-hepatic disease (Chang et al., 2011).
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As demonstrated by previous studies of SBRT for liver metas-
tases inmultiple different histologies and speciﬁcally for colorectal
metastases, the optimal dose, and fractionation scheme has not
yet been determined. A dose–response effect has been observed
in heterogeneous groups of patients, with improved local con-
trol with higher fractionated SBRT dose (60Gy as compared with
30Gy), or higher single-fraction SBRT dose (22–26 vs. 14–20Gy;
Herfarth et al., 2004; Rule et al., 2011). The safety and efﬁcacy of
higher–dose fractionated SBRT (60Gy in three fractions) has been
demonstrated, with local control rates of 92% at 2 years and low
rates of grade 3 or higher toxicity (Rusthoven et al., 2009). We did
not observe a dose–response relationship.
ONGOING STUDIES
A summary of ongoing studies regarding the use of SBRT and con-
ventional radiotherapy in the treatment of liver metastases is pro-
vided in Table 3. These trials utilize higher doses of RT compared
with our study and will provide important data regarding clini-
cal outcomes and quality of life after SBRT. The outcomes from
all of these trials will help to inform future therapeutic decision-
making regarding patient selection, prognosis, and quality of life
after treated with SBRT for liver metastases.
THE FUTURE OF SBRT FOR HEPATIC COLORECTAL METASTASES
Despite the current ongoing trials, there will still be a signiﬁcant
need for robust data regarding the utility and efﬁcacy of SBRT for
the treatment of liver metastases. Future directions for research
would optimally evaluate which patients are eligible for liver SBRT,
including whether SBRT might be a reasonable alternatively to
limited surgery, or only used when surgery is not an option. Addi-
tionally, dosimetric parameters need optimization to determine
the most effective total and fractional doses to achieve maximal,
long-term local control.
Although SBRT can be an important part of treatment for these
patients, they also are likely to utilize other therapeutic techniques
for local or distant control, which might include radiofrequency
ablation (RFA), transarterial chemoembolization (TACE), surgery,
or systemic chemotherapy. Further research is needed to under-
stand the interaction of these multiple therapeutic techniques and
todetermine thebest sequencingof thesemodalities for primaryor
salvage therapy. In addition to examining optimal therapy in this
highly speciﬁc patient population, lessons learned in the treatment
of hepatic metastases from CRC with SBRT could be extrapolated
and further studied to determine optimum treatment strategies
for other primary malignancies which might similarly have long-
term survival even in the setting of hepatic metastases, such as
breast cancer.
Our study focused on the technique of CyberKnife SBRT and
on local control, but more research is needed regarding the overall
impact of SBRT and control of hepatic disease on patient-reported
outcomes (PRO) in the palliative setting, and in overall disease-
free and overall survival in both patients treated with curative and
palliative intent. Finally, as SBRT techniques improve, comparative
effectiveness researchwill also be needed to compare among local–
regional therapies, including surgery, RFA, TACE, and SBRT, to
determine the best therapeutic approaches for individual patients.
LIMITATIONS
Limitations include the retrospective nature of this series and het-
erogeneous treatment schedules: there was a wide range of doses
prescribed, and a variety of fractionation schema. Although this
demonstrates that several different types of technical approaches
may be reasonable for the treatment of liver metastases fromCRC,
our study does not reﬁne the prescription technique to optimize
local control. Patients alsowere not comparedwith those undergo-
ing alternate loco-regional treatment modalities, including TACE
or RFA. Finally, patient follow-up needs to be longer in order to
examine both local control and impact of local control on local–
regional control and its interplay with distant disease control and,
ultimately, on survival.
CONCLUSION
This study demonstrates that SBRT for hepatic metastases from
CRC is safe and feasible in a small patient cohort, including those
who would not have been candidates for hepatectomy with neg-
ative margins. Although the majority of patients died within our
follow-up,many had effectively controlled local disease after treat-
ment. Our methodology is similar to those presented in recently
published trials, although our median BED10 is lower than some
trials demonstrated to be most effective for dose-escalation. Given
the size of our sample, local control and overall survival among
our patients compare favorably with published series. Toxicity in
the presented series also compares favorably with historical data.
Although some trials report small numbers of grade 3–5 events,
our study demonstrates only one grade 3 liver enzyme abnor-
mality. This study hypothesis-generating, serving as a basis for
designing a prospective clinical study to better characterize patient
eligibility, optimize combinations of therapeutic modalities, and
Table 3 | Ongoing clinical trials regarding radiotherapy in the treatment of liver metastases.
Trial Timing Method Dose Outcomes Reference
NCT01318447 Start: January, 2011, interim: January,
2014, complete: January, 2017
Phase II,
SBRT
BED10 = 112, SBRT Response, toxicity, local
control, survival, quality of life
Clinicaltrials.gov (2011a)
NCT00923897 Start: February, 2007, complete:
November, 2012
Phase II BED10 = 14.4,
conventional RT
Quality of life Clinicaltrials.gov (2011b)
NCT01162278 Start: July, 2010, interim: July, 2014,
complete: July, 2018
Phase I BED10 = 157.5–300,
SBRT
Safety response, toxicity,
local control, survival
Clinicaltrials.gov (2011c)
NCT00914615 Start: August, 2007, complete: August,
2010
Phase II (Not provided) Toxicity, survival, quality of
life, cytokine, response
Clinicaltrials.gov (2011d)
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deﬁne treatment parameters to maximize local control, survival,
and quality of life following SBRT.
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